Embed Size (px)
Citation preview
June 22-24, 2021Delivered in a 100% Virtual FormatPacific Standard Time (PST)
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
CAR AND T CELL THERAPIES: IMPROVE THE SAFETY & EFFICACY OF YOUR NOVEL CAR MODALITIES THROUGH TRANSLATIONAL SCIENCE AND CUTTING EDGE CLINICAL DATA
SHIPRA DAS,Team Leader,
Immuno-Oncology,CELLECTIS,
USA
BIRGIT SCHULTES,Vice President, Immunology
(Cell Therapies),INTELLIA THERAPEUTICS,
USA
PAUL LAMMERS,President & CEO,
TRIUMVIRA IMMUNOLOGICS,
USA
REGISTER BY APRIL 30TH AND
SAVE $100
Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors
BLAKE AFTAB,Vice President, Preclinical & Translational Science,
ATARA BIOTHERAPEUTICS
USA
Comprehensive and Dynamic ContentOur 100% virtual scientific agenda includes novel case studies and interactive panel discussions designed to help you revolutionize cell and gene engineering. Your virtual attendee pass includes access to all presentations, live speaker Q&A sessions, along with a 30-day post event window to watch the presentations on demand
LEARN ABOUT NOVEL TECHNOLOGIESFast-track your early phase development by watching live product and technology demonstrations with leading solution providers working across the entire spectrum of CAR & T Cell Therapies development and production.
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
NOVEL TECHNOLOGICAL ADVANCES & APPLICATIONS TO HELP YOU REVOLUTIONIZE EARLY PHASE DEVELOPMENTOur industry-leading virtual event platform provides you direct access to the brightest scientific minds and leading solution providers in the CAR & T Cell Therapies space.
Virtual NetworkingOur virtual networking platform will make it easy to connect face-to-face with the right people via video chat, ensuring you can have the critical conversations that matter with the people that matter to you. Leverage advanced search capabilities to identify opportunities and potential partners and reate your personal profile to indicate who you are, what you’re looking for and who you want to meet.
22REGISTER BY APRIL 30TH AND
$100SAVE
AGENDA DAY ONE: JUNE 22ND 2021
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
3
9:45am Opening Remarks from Sarah Lintern, Conference Director)
9.5am Conference Opening and Welcome
NON-CLINICAL & TRANSLATIONAL CONSIDERATIONS AND STRATEGIES 10:05am Preclinical CAR T Discovery Candidate Selection for Targets such as CD70 Or DLL3
Siler Panowski, Director of Biology, Solid Tumors, Allogene, USA
10:30am Creating a Feedback Loop Between Clinical Trials and Translational Science for Product ImprovementSpeaker from HESI CT-TRACS committee
10:55am Spotlight Presentation
11:15am Speaker Q&A
11.35am – Morning Coffee and Networking
NEXT GENERATION SOLID TUMOUR APPROACHES 12:00pm In vivo engineering of CAR-T cells: A promising new approach to cancer immunotherapy
Shon Green, Senior Director, Translational Sciences, Umoja Biopharma, USA
12:25pm CAR-T therapy for solid tumors: The Road Ahead Shipra Das, Team Leader Immuno-Oncology, Cellectis, USA
12.50pm Targeted CART Approaches for Solid TumoursAstero Klampatsa, Team Leader, Institute of Cancer Research, UK
1:10pm Speaker Q&A
1:30 – Sponsored Luncheon Presentations
NEXT GENERATION SOLID TUMOUR APPROACHES2.15pm Switchable CAR-T for Solid Tumours
Travis Young, VP, Biologics, Calibr, USA
2:40pm Solid Tumour Targeted CAR’s with Armor Tailored for Solid Tumour Microenvironments Blake Aftab, Vice President, Preclinical & Translational Science, Atara Biotherapeutics, USA
3:05pm 3T Case Study - Identification of Novel Targets for the Treatment of Solid Tumours in Broad Patient PopulationsHanspeter Gerber, CSO and SVP, 3T Biosciences, USA
3:30pm TCR Identification in Solid Tumour IndicationsFelix Lorenz, Head of Captain T Cell, Max-Delbrück-Center for Molecular Medicine (MDC Berlin), Germany
3:50pm Speaker Q&A
4:10pm End of Day One
REGISTER BY APRIL 30TH AND
$100SAVE
AGENDA DAY TWO: JUNE 23RD 2021
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
4
9.50am Conference Opening and Welcome
IS THE FUTURE ALLOGENEIC? CARNK, IPSC AND FUTURE CONSIDERATIONS10:05am Harnessing of Blood Derived Gamma Delta T Cells for Cancer Immunotherapy
John Maher, CSO, Leucid Bio, Clinical Senior Lecturer in Immunology, Kings College London, UK
10:30am Clinical Development with Two Distinct Proprietary and Unique Non-Gene Edited Allogeneic Technology Approaches
Frederic F. Lehmann, Head Global Clinical Development and Medical Affairs, Vice President, Celyad, Belgium
10:55am PANEL: Next Generation CAR Strategies – Allo, NK and Macrophages for Treating Multiple Patients • What are the current trends and successes seen here?• Will this replace autologous treatments • Will allo see success in both haem and solid tumour indications?John Maher, CSO, Leucid Bio, Clinical Senior Lecturer in Immunology, Kings College London, UKFrederic F. Lehmann, Head Global Clinical Development and Medical Affairs, Vice President, Celyad, BelgiumJohn Tomtishen, Director of Manufacturing, Technical Operations, Legend Biotech, USADan MacLeod, Senior Director Cell Therapy Discovery, Precision BioSciences Inc., USA
11:15am Speaker Q&A
11.35am – Morning Coffee and Networking
NOVEL CAR AND T CELL MODALITIES – SAFETY, EFFICACY AND CLINICAL DATA 12:00pm Driving lupus out with CARs
Marko Radic, Associate Professor, Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, USA
12:25pm Clinical Case Study – Novel CARs & TCRsPaul Lammers, President & CEO, Triumvira Immunologics, USA
12.50pm Spotlight Presentation
1:10pm Speaker Q&A
1.30 – Sponsored Luncheon Presentations
NOVEL CAR AND T CELL MODALITIES – SAFETY, EFFICACY AND CLINICAL DATA 2.15pm CAR Macrophage Case Study
Michael Klichinsky, Co-Founder & VP, Discovery Research, Carisma Therapeutics, USA
2:40pm Predictive Biomarkers of Response and Toxicity to Anti-CD19 CAR T Cell TherapyJohn Rossi, Senior Director, Translational Medicine, Kite, A Gilead Company, USA
3:05pm CRISPR Screens for Finding New or Selecting T Cell Edits for Different Solid TumoursBirgit Schultes, Vice President, Immunology (Cell Therapies), Intellia Therapeutics, Inc., USA
3:30pm Spotlight Presentation
3:50pm Speaker Q&A
4:10pm End of Day Two
REGISTER BY APRIL 30TH AND
$100SAVE
AGENDA DAY THREE: JUNE 24TH 2021
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
5
9.50am Conference Opening and Welcome
NOVEL CAR AND T CELL MODALITIES – SAFETY, EFFICACY AND CLINICAL DATA 10:05am Translational Lessons from Pivotal Axi-Cel Trial (ZUMA-1): Implications for Safety, Efficacy and Next Generation Products
Simone Filosto, Principal Scientist I, Cell Biology, Kite Pharma, USA
10:30am Contextual Secretion of Nanoscale, Antigen-Dependent IL-12 By CAR T Cells for Cancer TreatmentZhifen Yang, Associate Director, Refuge Biotechnologies, USA
10:55am Spotlight Presentation
11:15am Speaker Q&A
11.35am – Morning Coffee and Networking
NOVEL CAR AND T CELL MODALITIES – SAFETY, EFFICACY AND CLINICAL DATA 12:00pm Fusion Proteins to Bridge CAR19 T Cell and Tumor Cells
Paul Rennert, President & CSO, Aleta BioTherapeutics, USA
12:25pm DAP10/12 co-stimulation/Signaling Domains & HuLym-1 CAR T-cells Targeting HLA-DR Expressed by Lymphomas and Most Solid TumorsAlan L Epstein, Professor of Pathology, Keck School of Medicine USC, USA
12.50pm Spotlight Presentation
1:10pm Speaker Q&A
1.30 – Sponsored Luncheon Presentations
MANUFACTURING, PATIENT JOURNEY & TREATMENT APPROACH STRATEGIES 2.15pm Centralized vs. Decentralized Patient Treatment Approaches
Allison Matthews, Senior Service Designer, Innovation and Design, Mayo Clinic, USA
2:40pm Progress in Manufacturing of Lentiviral Vectors in Suspension SystemsDavid Hsu, Senior Director, City of Hope, USA
3:00pm Spotlight Presentation
3:20pm End of Day Three
REGISTER BY APRIL 30TH AND
$100SAVE
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
6
MEET THE PEOPLE BEHIND THE PRODUCTS AND GET THE ANSWERS YOU NEEDCONTACT US TODAY TO BUILD YOUR CUSTOM SPONSORSHIP PACKAGE
Perri LucatelloHead of Portfolio Sales, Cell & Gene Therapy [email protected]
SPONSOR BENEFITS
Unparalleled Audience ReachReach a massive digital audience of bioprocessing leaders through email, social, and ad campaigns - plus arrange one-to-one meetings pre-event.
Inbound Leads & EngagementSee who expressed interest in your company and colleagues as well as who engaged with your content and sponsor profile. Network with attendees directly and create a 1-to-1 chat to exchange details within the platform. (Note: Due to GDPR compliance, no email addresses are listed on the platform).
Enhanced Thought LeadershipDemonstrate your expertise in a session where attendees can ask questions and presenters can poll the audience optimizing audience interaction.
Extended Branding ExposureMake an impression on a highly qualified digital audience of decision makers before, during, and after the live event.
No Travel CostsEngage decision makers and extend your reach without pulling your staff out of the office.
REGISTER BY APRIL 30TH AND
$100SAVE
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
WAYS TO REGISTER3
EASIEST:https://informaconnect.com/car-t/
FOR EACH EVENT, YOU’LL RECEIVE:• Access to all presentations across all tracks• Access to all live speaker Q&A sessions during the event dates• Access to the full attendee list with meeting request
functionalities• Access to the virtual technology showcase hub from our sponsors• Access to re-watch presentations from this event on-demand
for an additional 30 days after the event• Ability to present a virtual poster at no additional charge Questions About Registration? Contact Event Marketing Manager Shahana Chowdhury at [email protected]
PRESENT A VIRTUAL SCIENTIFIC POSTER WITH YOUR ALL ACCESS PASSShare your company’s latest research by presenting a virtual scientific poster at Next Generation CAR & T Cell Therapies. Deadline: Friday 21st May 2021. In order to present a poster, you must be a registered attendee and submit your poster abstract by March 26, 2021.
SUBMIT POSTER HERE
VIRTUAL PASS TYPES SAVE UP TO $100 REGISTER BY APRIL 30 STANDARD RATE
Industry 3 Day All Access Pass $1499 $1599
Academic/Government 3 Day All Access Pass $399 $499
CALL888-670-8200 or +1.941.554.3500
* Additional savings are available to full time academic or government employees with no industry affiliation. View academic/government pricing online at https://informaconnect.com/car-t/
7REGISTER BY APRIL 30TH AND
$100SAVE
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
STAY INFORMED YEAR-ROUND WITH BIOPROCESS INTERNATIONAL
For Full Details On Our cell & gene therapy manufacturing & commercialization Event Schedule, Visit: https://informaconnect.com/car-t/
Next GenerationCAR & T Cell Therapies
June 22-24, 2021
November, 2021Milan
September 20-23, 2021Boston
October 26-28, 2021Hyattsville, Maryland
December 2021Vienna
VIRTU
AL EV
ENTS
LIVE,
IN-P
ERSO
N EV
ENTS
March 29-31, 2021
April 27-28, 2021
8REGISTER BY APRIL 30TH AND
$100SAVE
CELLTHERAPYIC | #NEXTGENCARThttps://informaconnect.com/car-t/
DIGITAL WEEK
February 22-25, 2021
June 21-24, 2021
February 16-19, 2021
May 24-27, 2021
November 2021
April 5-8, 2021
DIGIT
AL W
EEKS
Digital Weeks are free-to-attend live webinar series showcasing today’s novel bioprocessing technologies designed to accelerate speed to market for your biologics, mAbs, vaccines and novel products.
STAY INFORMED YEAR-ROUND WITH BIOPROCESS INTERNATIONAL
9
For Full Details On Our cell & gene therapy manufacturing & commercialization Event Schedule, Visit: https://informaconnect.com/car-t/
REGISTER BY APRIL 30TH AND
$100SAVE
